Norwalk Leslie V Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
4
Insider Sells Sum
$1.86M

Insider Activity of Norwalk Leslie V

According to the SEC Form 4 filings, Norwalk Leslie V, being in a position of

  1. director at Globus Medical, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 6000 shares for $557,600,
    over all time since 2024-03-15, has bought 0 shares, and sold 17590 shares for $1.18M.

Biography of Norwalk Leslie V

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $2,531,4827100

Comparison of Insiders on Amount of Buys and Sells

2026-07-28SaleNeurocrine Biosciences, Inc.
NBIX
director
1,250
0.0012%
$182.01$227,508-17.51%
2026-06-04SaleNeurocrine Biosciences, Inc.
NBIX
director
1,250
0.0012%
$168.06$210,072-6.49%
2026-05-12SaleNeurocrine Biosciences, Inc.
NBIX
director
3,810
0.0038%
$155.01$590,601+0.49%
2026-01-08SaleGlobus Medical, Inc.
GMED
director
2,000
0.0016%
$101.10$202,200-12.35%
2025-12-16SaleNeurocrine Biosciences, Inc.
NBIX
director
1,190
0.0012%
$155.09$184,558-3.54%
2025-12-15SaleNeurocrine Biosciences, Inc.
NBIX
director
5,000
0.005%
$152.23$761,144-6.82%
2025-12-12SaleGlobus Medical, Inc.
GMED
director
4,000
0.0031%
$88.85$355,400-2.53%
2024-07-11SaleGlobus Medical, Inc.
GMED
director
1,000
0.0008%
$70.00$70,000+2.57%
2024-05-17SaleNeurocrine Biosciences, Inc.
NBIX
director
1,106
0.0011%
$141.82$156,850-11.84%
2024-03-15SaleGlobus Medical, Inc.
GMED
director
10,590
0.0079%
$51.99$550,574+38.56%
2024-02-27SaleNeurocrine Biosciences, Inc.
NBIX
director
8,000
0.008%
$135.67$1.09M-0.15%
Total: 11
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.